Resources Blog Technological Innovations in Antibody Production

Technological Innovations in Antibody Production

Biointron 2024-02-16 Read time: 3 mins
Electrofusion Technology. Image credit: 10.1002/biot.202200428

The field of antibody production has witnessed significant technological advancements over the past years, particularly in hybridoma technology, which remains a cornerstone for monoclonal antibody (mAb) production.

Electrofusion Technology in Hybridoma Preparation

Electrofusion technology can be applied as a cell engineering technique for hybridoma preparation. This method offers substantial improvements in efficiency and control over traditional polyethylene glycol-mediated cell fusion. Electrofusion involves electric field intensity, number of pulses, and pulse duration. However, key challenges in adopting electrofusion include selecting appropriate instruments, optimizing electrical parameters, and precisely controlling cell conditions. Despite this, electrofusion represents a promising advancement for enhancing the specificity and yield of monoclonal antibodies.1

Hybridoma Cell Screening and Expansion

The process of generating monoclonal antibodies through hybridoma technology involves screening hybridoma cells to select those producing the desired antibodies. This is typically achieved using enzyme-linked immunosorbent assay (ELISA) techniques, among others, to identify antibodies with the right specificity. Following screening, hybridomas that produce the desired antibodies are cloned and propagated to obtain stable cell populations for large-scale antibody production. This expansion can be performed either in vitro, using tissue culture techniques, or in vivo, by inoculating hybridoma cells into the abdomen of a mouse. However, the technology is not without limitations, such as long production times, resource-intensive processes, susceptibility to contamination, and challenges in generating short peptides and fragment antigens.

Clinical Significance and Applications

Hybridoma technology's clinical significance is vast, providing monoclonal antibodies for various diagnostic tests, cancer treatments, and research applications. The specificity and reliability of monoclonal antibodies produced via hybridoma technology have made it an indispensable tool in the diagnosis and treatment of numerous diseases. This technology enables the production of antibodies for detecting foreign antigens, identifying different strains of pathogens, and even treating viral diseases such as AIDS. Moreover, monoclonal antibodies are instrumental in radioimmunodetection and radioimmunotherapy of cancer, highlighting their critical role in modern medicine.2 Biointron offers hybridoma sequencing services for antibody discovery and production.


  1. Kou, J., Shen, J., Wang, Z., & Yu, W. (2023). Advances in hybridoma preparation using electrofusion technology. Biotechnology Journal, 18(10), 2200428.

  2. Mitra, S., & Tomar, P. C. (2021). Hybridoma technology; advancements, clinical significance, and future aspects. Journal of Genetic Engineering and Biotechnology, 19(1), 1-12.

Subscribe to our Blog

Recent Blog

Computational antibody methods schematic. DOI: 10.1093/bib/bbz095The development of therapeutic antibodies has been significantly enhanced by advancements in computational methods and artificial intelligence (AI). These technologies have streamlined the antibody discovery process, improving the abil

May 27, 2024

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.